by Summary:
California-based pharmaceutical giant Gilead Sciences has announced that a five-day course of its antiviral drug Remdesivir — shown in tests to effectively fight COVID-19 — will cost ,120 to Americans with health insurance and ,340 to those on Medicaid. Yet research published in April calculated that the drug could be produced at a profit for as little as %excerpt%.93 per day. The study, led by Dr. Andrew Hill from the Department of Translational Medicine, University of Liverpool, U.K., and published in the Journal of Virus Eradication, found that a five-day course of lifesaving Remdesivir could be mass-produced for less than the cost of a Subway sandwich. So cheap is the drug that the saline solution and the syringe needed to administer it would be more costly. MintPress spoke with Dr.
Topics:
Mike Norman considers the following as important:
This could be interesting, too:
California-based pharmaceutical giant Gilead Sciences has announced that a five-day course of its antiviral drug Remdesivir — shown in tests to effectively fight COVID-19 — will cost $3,120 to Americans with health insurance and $2,340 to those on Medicaid. Yet research published in April calculated that the drug could be produced at a profit for as little as $0.93 per day.California-based pharmaceutical giant Gilead Sciences has announced that a five-day course of its antiviral drug Remdesivir — shown in tests to effectively fight COVID-19 — will cost ,120 to Americans with health insurance and ,340 to those on Medicaid. Yet research published in April calculated that the drug could be produced at a profit for as little as %excerpt%.93 per day. The study, led by Dr. Andrew Hill from the Department of Translational Medicine, University of Liverpool, U.K., and published in the Journal of Virus Eradication, found that a five-day course of lifesaving Remdesivir could be mass-produced for less than the cost of a Subway sandwich. So cheap is the drug that the saline solution and the syringe needed to administer it would be more costly. MintPress spoke with Dr.
Topics:
Mike Norman considers the following as important:
This could be interesting, too:
Matias Vernengo writes Milei’s Psycho Shock Therapy
Bill Haskell writes Population Growth Outcomes
Robert Vienneau writes Books After Marx
Joel Eissenberg writes Undocumented labor: solutions, not scapegoating
The study, led by Dr. Andrew Hill from the Department of Translational Medicine, University of Liverpool, U.K., and published in the Journal of Virus Eradication, found that a five-day course of lifesaving Remdesivir could be mass-produced for less than the cost of a Subway sandwich. So cheap is the drug that the saline solution and the syringe needed to administer it would be more costly. MintPress spoke with Dr. Hill, who was dismayed by the company’s announcement.
Mint Press
Public Outcry Follows Gilead Decision to Charge $3000 for COVID Drug that Costs Pennies to Produce